205 related articles for article (PubMed ID: 35936719)
1. A Network-Guided Approach to Discover Phytochemical-Based Anticancer Therapy: Targeting MARK4 for Hepatocellular Carcinoma.
Ahmed S; Mobashir M; Al-Keridis LA; Alshammari N; Adnan M; Abid M; Hassan MI
Front Oncol; 2022; 12():914032. PubMed ID: 35936719
[TBL] [Abstract][Full Text] [Related]
2. Vanillin-Isatin Hybrid-Induced MARK4 Inhibition As a Promising Therapeutic Strategy against Hepatocellular Carcinoma.
Ahmed S; Queen A; Irfan I; Siddiqui MN; Abdulhameed Almuqdadi HT; Setia N; Ansari J; Hussain A; Hassan MI; Abid M
ACS Omega; 2024 Jun; 9(24):25945-25959. PubMed ID: 38911744
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Coumarin as Microtubule Affinity-Regulating Kinase 4 Inhibitor That Sensitize Hepatocellular Carcinoma to Paclitaxel.
Shen X; Liu X; Wan S; Fan X; He H; Wei R; Pu W; Peng Y; Wang C
Front Chem; 2019; 7():366. PubMed ID: 31179271
[TBL] [Abstract][Full Text] [Related]
4. Microtubule-associated protein/microtubule affinity-regulating kinase 4 (MARK4) plays a role in cell cycle progression and cytoskeletal dynamics.
Rovina D; Fontana L; Monti L; Novielli C; Panini N; Sirchia SM; Erba E; Magnani I; Larizza L
Eur J Cell Biol; 2014; 93(8-9):355-65. PubMed ID: 25123532
[TBL] [Abstract][Full Text] [Related]
5. Investigation of molecular mechanism of recognition between citral and MARK4: A newer therapeutic approach to attenuate cancer cell progression.
Naz F; Khan FI; Mohammad T; Khan P; Manzoor S; Hasan GM; Lobb KA; Luqman S; Islam A; Ahmad F; Hassan MI
Int J Biol Macromol; 2018 Feb; 107(Pt B):2580-2589. PubMed ID: 29079437
[TBL] [Abstract][Full Text] [Related]
6. Integrated System Pharmacology Approaches to Elucidate Multi-Target Mechanism of
Khalid HR; Aamir M; Tabassum S; Alghamdi YS; Alzamami A; Ashfaq UA
Molecules; 2022 Sep; 27(19):. PubMed ID: 36234758
[TBL] [Abstract][Full Text] [Related]
7. Identification and evaluation of bioactive natural products as potential inhibitors of human microtubule affinity-regulating kinase 4 (MARK4).
Mohammad T; Khan FI; Lobb KA; Islam A; Ahmad F; Hassan MI
J Biomol Struct Dyn; 2019 Apr; 37(7):1813-1829. PubMed ID: 29683402
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic targeting of microtubule affinity-regulating kinase 4 in cancer and neurodegenerative diseases.
Alam M; Ahmed S; Abid M; Hasan GM; Islam A; Hassan MI
J Cell Biochem; 2023 Sep; 124(9):1223-1240. PubMed ID: 37661636
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of human microtubule affinity-regulating kinase 4 inhibitors: fluorescence binding studies, enzyme, and cell assays.
Naz F; Sami N; Naqvi AT; Islam A; Ahmad F; Imtaiyaz Hassan M
J Biomol Struct Dyn; 2017 Nov; 35(14):3194-3203. PubMed ID: 27748164
[TBL] [Abstract][Full Text] [Related]
10. Impact of glioblastoma multiforme associated mutations on the structure and function of MAP/microtubule affinity regulating kinase 4.
Naqvi AAT; Jairajpuri DS; Hussain A; Hasan GM; Alajmi MF; Hassan MI
J Biomol Struct Dyn; 2021 Mar; 39(5):1781-1794. PubMed ID: 32141394
[TBL] [Abstract][Full Text] [Related]
11. MARK4 is a novel microtubule-associated proteins/microtubule affinity-regulating kinase that binds to the cellular microtubule network and to centrosomes.
Trinczek B; Brajenovic M; Ebneth A; Drewes G
J Biol Chem; 2004 Feb; 279(7):5915-23. PubMed ID: 14594945
[TBL] [Abstract][Full Text] [Related]
12. Linagliptin and Empagliflozin Inhibit Microtubule Affinity Regulatory Kinase 4: Repurposing Anti-Diabetic Drugs in Neurodegenerative Disorders Using In Silico and In Vitro Approaches.
Atiya A; Das Gupta D; Alsayari A; Alrouji M; Alotaibi A; Sharaf SE; Abdulmonem WA; Alorfi NM; Abdullah KM; Shamsi A
ACS Omega; 2023 Feb; 8(7):6423-6430. PubMed ID: 36844587
[TBL] [Abstract][Full Text] [Related]
13. Microtubule affinity-regulating kinase 4: structure, function, and regulation.
Naz F; Anjum F; Islam A; Ahmad F; Hassan MI
Cell Biochem Biophys; 2013 Nov; 67(2):485-99. PubMed ID: 23471664
[TBL] [Abstract][Full Text] [Related]
14. Yupingfeng San exhibits anticancer effect in hepatocellular carcinoma cells via the MAPK pathway revealed by HTS
Pei T; Dai Y; Tan X; Geng A; Li S; Gui Y; Hu C; An J; Yu X; Bao X; Wang D
J Ethnopharmacol; 2023 Apr; 306():116134. PubMed ID: 36627003
[TBL] [Abstract][Full Text] [Related]
15. Systems Network Pharmacology-Based Prediction and Analysis of Potential Targets and Pharmacological Mechanism of
Hu Y; Yang L; Lu Y; Wang Y; Jiang J; Liu Y; Cao Q
Evid Based Complement Alternat Med; 2022; 2022():2116006. PubMed ID: 36193154
[TBL] [Abstract][Full Text] [Related]
16. Myricetin inhibits breast and lung cancer cells proliferation via inhibiting MARK4.
Anwar S; Khan S; Anjum F; Shamsi A; Khan P; Fatima H; Shafie A; Islam A; Hassan MI
J Cell Biochem; 2022 Feb; 123(2):359-374. PubMed ID: 34751461
[TBL] [Abstract][Full Text] [Related]
17. Suggestive evidence on the involvement of polypyrimidine-tract binding protein in regulating alternative splicing of MAP/microtubule affinity-regulating kinase 4 in glioma.
Fontana L; Rovina D; Novielli C; Maffioli E; Tedeschi G; Magnani I; Larizza L
Cancer Lett; 2015 Apr; 359(1):87-96. PubMed ID: 25578778
[TBL] [Abstract][Full Text] [Related]
18. Rosmarinic Acid Exhibits Anticancer Effects via MARK4 Inhibition.
Anwar S; Shamsi A; Shahbaaz M; Queen A; Khan P; Hasan GM; Islam A; Alajmi MF; Hussain A; Ahmad F; Hassan MI
Sci Rep; 2020 Jun; 10(1):10300. PubMed ID: 32587267
[TBL] [Abstract][Full Text] [Related]
19. Designing New Kinase Inhibitor Derivatives as Therapeutics Against Common Complex Diseases: Structural Basis of Microtubule Affinity-Regulating Kinase 4 (MARK4) Inhibition.
Naz F; Shahbaaz M; Bisetty K; Islam A; Ahmad F; Hassan MI
OMICS; 2015 Nov; 19(11):700-11. PubMed ID: 26565604
[TBL] [Abstract][Full Text] [Related]
20. Microtubule affinity regulating kinase 4 promoted activation of the NLRP3 inflammasome-mediated pyroptosis in periodontitis.
Wang L; Pu W; Wang C; Lei L; Li H
J Oral Microbiol; 2022; 14(1):2015130. PubMed ID: 34992737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
